Study Summary: Systemic bioavailability of topical diclofenac sodium gel 1%
Study Objective & Methodology
A seven-week, single-center, randomized, open-label, multiple-dose, 3-way crossover study conducted in healthy volunteers ≥ 50 years (n=40) to compare the systemic bioavailability and pharmacodynamics of topical diclofenac sodium gel 1% vs. oral diclofenac sodium 50-mg tablets.
- Systemic exposure and maximum plasma concentrations of diclofenac were significantly lower with diclofenac gel 1% than with oral diclofenac sodium
- Platelet aggregation and COX-1 were minimally inhibited by DSG when compared with DS Tab which ensures low risk of cardiovascular health related AEs
- Topical diclofenac, with a more favorable safety profile, represents a useful alternative to oral diclofenac therapy in pain management
Download our study summary below to learn more about how diclofenac sodium gel 1% showed significantly lower systemic exposure and fluctuation in plasma levels compared with oral diclofenac sodium for osteoarthritis.
Request Haleon product samples, which are subject to eligibility requirements and availability.